U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H9Cl2N3
Molecular Weight 230.0941
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLONIDINE

SMILES

c1cc(c(c(c1)Cl)NC2=NCCN2)Cl

InChI

InChIKey=GJSURZIOUXUGAL-UHFFFAOYSA-N
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)

HIDE SMILES / InChI

Molecular Formula C9H9Cl2N3
Molecular Weight 230.0941
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017407s037lbl.pdf | https://clinicaltrials.gov/ct2/show/NCT02177461 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022331lbl.pdf | https://clinicaltrials.gov/ct2/show/NCT00556959

Clonidine is a centrally acting α2 adrenergic agonist and imidazoline receptor agonist used to treat high blood pressure, attention deficit hyperactivity disorder, anxiety disorders, tic disorders, withdrawal (from either alcohol, opioids, or smoking), migraine, menopausal flushing, diarrhea, and certain pain conditions. Clonidine treats high blood pressure by stimulating α2 receptors in the brain, which decreases peripheral vascular resistance, lowering blood pressure. It has specificity towards the presynaptic α2 receptors in the vasomotor center in the brainstem. This binding decreases presynaptic calcium levels, thus inhibiting the release of norepinephrine (NE). It has also been proposed that the antihypertensive effect of clonidine is due to agonism on the I1 receptor (imidazoline receptor), which mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure. Clonidines mechanism of action in the treatment of ADHD is to increase noradrenergic tone in the prefrontal cortex (PFC) directly by binding to postsynaptic α2A adrenergic receptors and indirectly by increasing norepinephrine input from the locus coeruleus. Clonidine indicated in the treatment of hypertension. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. The US Food and Drug Administration (FDA) has approved clonidine for the treatment of attention deficit hyperactivity disorder (ADHD), under the trade name of Kapvay alone or with stimulants in 2010, for pediatric patients aged 6–17 years.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CATAPRES-TTS-1

Approved Use

INDICATIONS & USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents.

Launch Date

4.66214388E11
Primary
KAPVAY

Approved Use

INDICATIONS AND USAGE. KAPVAY® is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications

Launch Date

1.25418235E12
Primary
CATAPRES-TTS-1

Approved Use

INDICATIONS & USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents.

Launch Date

4.66214388E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
443 pg/mL
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLONIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7313 pg × h/mL
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLONIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.57 h
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLONIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.25 mg 2 times / day multiple, oral
Studied dose
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Co-administed with::
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
unhealthy, 13 years
n = 1
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 13 years
Sex: M
Population Size: 1
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
Other AEs: Suicide attempt...
Other AEs:
Suicide attempt
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Population Size: 1
Sources:
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
Amphetamine
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 10 years
n = 102
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 10 years
Sex: M+F
Population Size: 102
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Disc. AE: Bradyphrenia...
AEs leading to
discontinuation/dose reduction:
Bradyphrenia (1%)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
0.1 mg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 76
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 76
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Disc. AE: Somnolence, Fatigue...
AEs leading to
discontinuation/dose reduction:
Somnolence (3.9%)
Fatigue (2.6%)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Disc. AE: Somnolence, Fatigue...
AEs leading to
discontinuation/dose reduction:
Somnolence (6.4%)
Fatigue (5.1%)
Constipation (1.3%)
Vomiting (1.3%)
Electrocardiogram QT prolonged (1.3%)
Rash (1.3%)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Other AEs: Dry mouth, Drowsiness...
Other AEs:
Dry mouth (below serious, 16 patients)
Drowsiness (below serious, 5 patients)
Lightheadedness (below serious, 6 patients)
Fatigue (below serious, 8 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Suicide attempt
0.25 mg 2 times / day multiple, oral
Studied dose
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Co-administed with::
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
unhealthy, 13 years
n = 1
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 13 years
Sex: M
Population Size: 1
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
Bradyphrenia 1%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
Amphetamine
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 10 years
n = 102
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 10 years
Sex: M+F
Population Size: 102
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Fatigue 2.6%
Disc. AE
0.1 mg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 76
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 76
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Somnolence 3.9%
Disc. AE
0.1 mg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 76
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 76
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Constipation 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Electrocardiogram QT prolonged 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Rash 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Vomiting 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Fatigue 5.1%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Somnolence 6.4%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Dry mouth below serious, 16 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Drowsiness below serious, 5 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Lightheadedness below serious, 6 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Fatigue below serious, 8 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Overview

Overview

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Letter: Dementia associated with clonidine therapy.
1975 Mar 15
Drug treatment options for irritable bowel syndrome: managing for success.
2001
Alpha2 adrenergic agonists for the management of opioid withdrawal.
2001
[Potentiation of local anesthesia in endonasal surgery].
2001
P75-expressing elements are necessary for anti-allodynic effects of spinal clonidine and neostigmine.
2001
Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure.
2001 Apr
Oops--wrong dose of epidural clonidine in children!
2001 Apr
Alpha2A-adrenoceptor mediated tachypnea in awake goats.
2001 Apr
Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA.
2001 Apr
Sodium-induced rise in blood pressure is suppressed by androgen receptor blockade.
2001 Apr
Blockade by agmatine of catecholamine release from chromaffin cells is unrelated to imidazoline receptors.
2001 Apr 6
Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy.
2001 Feb
The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes.
2001 Feb
Some behavioural effects of antidepressant drugs are time-dependent.
2001 Feb
Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.
2001 Feb
Interactions of ligands at angiotensin II-receptors and imidazoline receptors.
2001 Feb
Comparison of the effects of clonidine and hydroxyzine on haemodynamic and catecholamine reactions to microlaryngoscopy.
2001 Feb
The use of baclofen in cluster headache.
2001 Feb
Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.
2001 Feb
Nitric oxide and central antihypertensive drugs: one more difference between catecholamines and imidazolines.
2001 Feb
Mortality after coronary artery occlusion in different models of cardiac hypertrophy in rats.
2001 Feb
Inhibition of the I(h) current in isolated peripheral nerve: a novel mode of peripheral antinociception?
2001 Feb
Partial agonist clonidine mediates alpha(2)-AR subtypes specific regulation of cAMP accumulation in adenylyl cyclase II transfected DDT1-MF2 cells.
2001 Feb
Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.
2001 Feb
Noradrenergic dysfunction in the prefrontal cortex in depression: an [15O] H2O PET study of the neuromodulatory effects of clonidine.
2001 Feb 15
[Cardiovascular stress protection following anesthesia induction. Comparison of clonidine and esmolol].
2001 Jan
Do infant rats cry?
2001 Jan
Antagonistic effects of selective alpha1-adrenoceptor antagonists MDL73005EF and tamsulosin and partial agonists clonidine and tizanidine in rat thoracic aorta and rabbit iliac artery.
2001 Jan
Treatment of chronic hypertension with intravenous enalaprilat and transdermal clonidine.
2001 Jan
Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors.
2001 Jan
Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters.
2001 Jan
Effect of chronic morphine treatment on alpha(2)-adrenoceptor mediated autoinhibition of transmitter release from sympathetic varicosities of the mouse vas deferens.
2001 Jan
Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex.
2001 Jan
[Low sensitivity of IGF-I, IGFBP-3 and urinary GH in the diagnosis of growth hormone insufficiency in slowly-growing short-statured boys. Grupo Español de Estudio de la Talla Baja].
2001 Jan 13
Effects of antisense to the (alpha)2A-adrenoceptors administered into the region of the locus ceruleus on behaviors in plus-maze and sexual behavior tests in sham-operated and castrated male rats.
2001 Jan 15
Galanin/alpha2-adrenoceptor interactions in telencephalic and diencephalic regions of the rat.
2001 Jan 22
Frequency dependent alpha(2)-adrenoceptor mediated modulation of excitatory junction potentials in guinea-pig mesenteric artery.
2001 Jan 5
Clonidine in preterm-infant caudal anesthesia may be responsible for postoperative apnea.
2001 Jan-Feb
Premedication modifies the quality of sedation with propofol during regional anesthesia.
2001 Mar
Clonidine-induced antinociception and locomotor hypoactivity are reduced by dexamethasone in mice.
2001 Mar
Noradrenergic modulation of calcium currents and synaptic transmission in the olfactory bulb of Xenopus laevis tadpoles.
2001 Mar
Ultrasonic vocalizations of preweanling rats: involvement of both alpha(2)-adrenoceptor and kappa-opioid receptor systems.
2001 Mar
Effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain.
2001 Mar
The antinociceptive effect of intrathecal administration of epibatidine with clonidine or neostigmine in the formalin test in rats.
2001 Mar
The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats.
2001 Mar
Neural circuits regulating pulsatile luteinizing hormone release in the female guinea-pig: opioid, adrenergic and serotonergic interactions.
2001 Mar
Prevention of ischemic ventricular tachycardia of Purkinje origin: role for alpha(2)-adrenoceptors in Purkinje?
2001 Mar
Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies.
2001 Mar 14
Alpha-adrenergic agonists inhibit the dipsogenic effect of angiotensin II by their stimulation of atrial natriuretic peptide release.
2001 Mar 23
Linkage study of the alpha2A adrenergic receptor in attention-deficit hyperactivity disorder families.
2001 Mar 8
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018891s028lbl.pdf
Oral Initial Dose 0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose Maintenance Dose Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed. Transdermal: once every 7 days to a hairless area of intact skin on the upper outer arm or chest.
Route of Administration: Other
Neural membranes (P2 fractions) were prepared from the prefrontal cortex of human brains obtained at autopsy. Specific Clonidine binding was measured in 0.55 mL aliquots (50 mM Tris HCl, pH 7.5) of the neural membranes, which were incubated with [3H]RX821002 (1 nM) for 30 min at 25 °C in the absence or presence of the Clonidine (10^-12 M to 10^-3 M, 10 concentrations). Specific binding was determined and plotted as a function of the compound concentration. Incubations were terminated by diluting the samples with 5 mL of ice-cold Tris incubation buffer (4 °C). Membrane-bound [3H]RX821002 was separated by vacuum filtration through Whatman GF/C glass fiber filters. Then the filters were rinsed twice with 5 mL of incubation buffer and transferred to minivials containing 3 mL of OptiPhase “HiSafe” II cocktail and counted for radioactivity by liquid scintillation spectrometry.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:07 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:07 UTC 2021
Record UNII
MN3L5RMN02
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLONIDINE
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
CLONIDINE [VANDF]
Common Name English
CLONIDINE [WHO-DD]
Common Name English
ST-155-BS
Code English
CLONIDINE [HSDB]
Common Name English
CLONIDINE [USP-RS]
Common Name English
CLONIDINE EXTENDED RELEASE
Common Name English
CLONIDINE [MI]
Common Name English
CLONIDINE [USAN]
Common Name English
CLONIDINE [JAN]
Common Name English
CATARPRES-TTS
Brand Name English
CLONIDINE [MART.]
Common Name English
CLONIDINE [ORANGE BOOK]
Common Name English
2-((2,6-DICHLOROPHENYL)IMINO)IMIDAZOLIDINE
Systematic Name English
CLONIDINE [INN]
Common Name English
CLONIDINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC C02LC51
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-ATC S01EA04
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
NDF-RT N0000009918
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-VATC QC02LC01
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-ATC N02CX02
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-VATC QC02LC51
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-VATC QN02CX02
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
NCI_THESAURUS C29709
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
FDA ORPHAN DRUG 425614
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
NDF-RT N0000175554
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
FDA ORPHAN DRUG 34388
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-VATC QC02AC01
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-VATC QS01EA04
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
LIVERTOX 225
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-ATC C02AC01
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
WHO-ATC C02LC01
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C380
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
EPA CompTox
4205-90-7
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
DRUG BANK
DB00575
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
RXCUI
2599
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY RxNorm
FDA UNII
MN3L5RMN02
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
CAS
4205-90-7
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
ECHA (EC/EINECS)
224-119-4
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
MESH
D003000
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
IUPHAR
516
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
PUBCHEM
2803
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
LACTMED
Clonidine
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
USP_CATALOG
1140393
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY USP-RS
INN
2624
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
WIKIPEDIA
CLONIDINE
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
ChEMBL
CHEMBL134
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
DRUG CENTRAL
704
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
MERCK INDEX
M3650
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY Merck Index
HSDB
3040
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
EVMPD
SUB06730MIG
Created by admin on Fri Jun 25 20:54:07 UTC 2021 , Edited by admin on Fri Jun 25 20:54:07 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
TARGET -> AGONIST
SHORT-ACTING
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY